ABOUT OUR TRIAL
Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease.
The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications. In addition, this study will help to determine whether improvement in endoscopic healing is seen after 16 weeks or after 26 weeks of treatment.
For more information, check out our webinars about the trial.
Thank you for your interest in participating in Qu Biologics’ Phase 2 clinical trial of an investigational new treatment for Crohn’s disease. To apply to participate, you will be asked to take a short questionnaire (16 questions) so that a clinical doctor can assess your eligibility for this trial. The questionnaire and registration process will take about 10 minutes.
If at any time you have questions, you may speak with a Clinical Trial Representative at 1-877-223-8637 or firstname.lastname@example.org